The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.

Johnson & Johnson (JNJ) said that Health Canada has issued a Notice of Compliance for CARVYKTI (ciltacabtagene autoleucel) for the ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

Net Trade Sales of CARVYKTI: Approximately $286 million, an 87.6% increase year-over-year and a 53.2% increase ...

The study – which tested Carvykti in patients with one to three lines of prior therapy – gives J&J an opportunity to leapfrog Bristol-Myers Squibb and 2Seventy bio's rival BCMA CAR-T therapy ...

周三，Cantor Fitzgerald将Legend Biotech Corp. (NASDAQ:LEGN)的目标价从之前的82.00美元上调至83.00美元，同时维持对该股的增持评级。该公司分析师强调，最近美国血液学会（ASH）会议上anito-cel摘要数据引发的激烈讨论，已经盖过了Legend Biotech第三季度财报电话会议的关注度。 面对市场对竞争对手数据的反应，Legend Bio ...

在最近的财报电话会议上，传奇生物(NASDAQ: LEGN)报告其CARVYKTI治疗的净销售额显著增长，同比增长87.6%，达到约2.86亿美元。这一增长也反映了环比上一季度53.2%的大幅上涨。尽管如此，该公司仍面临1.25亿美元的净亏损，主要由于未实现的外汇损失。传奇生物的财务状况仍然稳健，拥有12亿美元的现金和等价物，强大的资产负债表确保公司的运营资金可持续到2026年。 要点摘要 CAR ...

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one prior therapy. The decision ...

Kostas Biliouris’s rating is based on several compelling factors that highlight Legend Biotech’s strong market position and future potential. The increasing uptake of Carvykti, driven by its ...

Carvykti shows high efficacy in real-world settings, with 89% response and 70% complete response rates among multiple myeloma patients. Despite many patients not meeting clinical trial criteria, ...

The Legend Biotech management team robustly defended the efficacy and safety profile of their product Carvykti, amidst market reactions to the competitor's data. The analyst noted that the ...